
|Videos|July 30, 2020
ASRS 2020: What Aviceda’s lead candidate AVD-104 may mean for dry AMD
Author(s)Alex Delaney-Gesing
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.
Advertisement
Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, Modern Retina's® group editorial director, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Phase 3 data support OTX-TKI's durability in wet AMD: 1 injection, 1 year
2
Retina World Congress 2026: Expanding the DME treatment algorithm beyond anti-VEGF
3
Retina World Congress 2026: Dry AMD — Geographic atrophy, photobiomodulation, and the road ahead
4
Q&A: Peripheral vision IOL's influence on driving performance
5



















